Antisense targeting of 3′ end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy:a new gene-silencing approach by Marsollier, Anne-Charlotte et al.
For Peer Review
 
 
 
 
 
 
Antisense targeting of 3’end elements involved in DUX4 
mRNA processing is an efficient therapeutic strategy for 
Facioscapulohumeral Dystrophy: a new gene silencing 
approach. 
 
 
Journal: Human Molecular Genetics 
Manuscript ID HMG-2015-D-01434.R1 
Manuscript Type: 2 General Article - UK Office 
Date Submitted by the Author: 14-Jan-2016 
Complete List of Authors: Marsollier, Anne-Charlotte; Pierre and Marie Curie University, UMRS974, 
INSERM U974, CNRS UMR7215, Myology Institute 
Ciszewski, Lukasz; Royal Holloway University of London, Centre of 
Biomedical Sciences, School of Biological Sciences 
mariot, virginie; Université Paris 6, INSERM U974, UMR 7215 CNRS, 
Institut de Myologie, UM 76 Université Pierre et Marie Curie 
Popplewell, Linda; Royal Holloway - University of London, School of 
Biological Sciences 
Voit, Thomas; Pierre and Marie Curie University, UMRS974, INSERM U974, 
CNRS UMR7215, Myology Institute 
Dickson, George; Molecular Cell Biology, Royal Holloway College-University 
of London 
Dumonceaux, Julie; Pierre and Marie Curie University, UMRS974, INSERM 
U974, CNRS UMR7215, Myology Institute 
Key Words: FSHD, muscle, gene silencing, DUX4, polyadenylation 
  
 
 
Human Molecular Genetics
For Peer Review
1 
 
Antisense targeting of 3’end elements involved in DUX4 mRNA processing is an efficient 
therapeutic strategy for Facioscapulohumeral Dystrophy: a new gene silencing approach. 
 
Anne-Charlotte Marsollier
1
, Lukasz Ciszewski
2#
, Virginie Mariot
1#
, Linda Popplewell
2
, 
Thomas Voit
1,§
, George Dickson
2
, Julie Dumonceaux
1*
 
 
1
Sorbonne Universités UPMC Univ Paris 06, Inserm, CNRS, Centre de Recherche en 
Myologie (CRM), GH Pitié Salpêtrière, 47 bld de l'hôpital, Paris 13, France 
2
Centre of Biomedical Sciences, School of Biological Sciences, Royal Holloway University 
of London, Surrey, TW20 0EX UK 
§
Present Address: NIHR Biomedical Research Centre, Institute of Child Health, University 
College London, 30 Guilford Street, London WC1N1EH, UK 
 
# equal contribution 
*Corresponding author: Julie Dumonceaux 
Corresponding author’s address: Sorbonne Universités UPMC Univ Paris 06, Inserm, CNRS, 
Centre de Recherche en Myologie (CRM), GH Pitié Salpêtrière, 47 bld de l'hôpital, Paris 13, 
France 
Corresponding author’s phone and fax: +33 1 42 16 57 16 and + 33 1 42 16 57 00 
Corresponding author’s e-mail address: julie.dumonceaux@upmc.fr 
 
  
Page 1 of 33 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
ABSTRACT 
Defects in mRNA 3’ end formation have been described to alter transcription termination, 
transport of the mRNA from the nucleus to the cytoplasm, stability of the mRNA and 
translation efficiency. Therefore, inhibition of polyadenylation may lead to gene silencing. 
Here, we choose Facioscapulohumeral Dystrophy (FSHD) as a model to determine whether or 
not targeting key 3’end elements involved in mRNA processing using antisense 
oligonucleotide drugs can be used as a strategy for gene silencing within a potentially 
therapeutic context. FSHD is a gain-of-function disease characterized by the aberrant 
expression of the DUX4 transcription factor leading to altered pathogenic deregulation of 
multiple genes in muscles. Here we demonstrate that targeting either the mRNA 
polyadenylation signal and/ or cleavage site is an efficient strategy to downregulate DUX4 
expression and to decrease the abnormally high pathological expression of genes downstream 
of DUX4. We conclude that targeting key functional 3’end elements involved in pre-mRNA 
to mRNA maturation with antisense drugs can lead to efficient gene silencing and is thus a 
potentially effective therapeutic strategy for at least FSHD. Moreover polyadenylation is a 
crucial step in the maturation of almost all eukaryotic mRNAs, and thus all mRNAs are 
virtually eligible for this antisense-mediated knockdown strategy. 
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INTRODUCTION 
The cleavage and polyadenylation of the 3’ end of pre-mRNAs are fundamental processing 
steps for the maturation of the vast majority of eukaryotic mRNAs. In human cells, these 
reactions are governed by more than 80 RNA-binding proteins and by regulatory cis-acting 
RNA sequence elements (for reviews see (1-3)). The key element dictating the cleavage is a 6 
nucleotide (nt) motif called the poly(A) signal (PAS). Most of the mammalian mRNAs 
contain the PAS consensus AAUAAA or AUUAAA hexamer or close variants (4-6) which is 
recognized by the multimeric set of cleavage and polyadenylation factors. This RNA-protein 
interaction determines the site of cleavage which usually occurs 10-30 nt downstream of the 
PAS. The second important element is a U/GU-rich sequence (Downstream Sequence 
Element, DSE) contacted by the cleavage stimulation factor (CstF) and located 30-60 nt 
downstream the PAS motif (for review see (7)). In most cases, these co-transcriptional 
maturations are required for nuclear export and stability of mRNAs, and their efficient 
translation (8), and thus consequently represent attractive and interesting drug and/or genetic 
targets for suppression of gene expression. Indeed, the functional importance of the 3’end 
mRNA processing has been highlighted by the discovery of mutations in the PAS cis-element 
causing or contributing to human diseases including haemotologic diseases, neurogenerative 
diseases, or cancer (for review see (9)).  
The aim of our study was to determine whether or not targeting elements involved in pre-
mRNA maturation (such as PAS or DSE) using antisense oligonucleotide drugs can be a 
strategy for gene silencing within a potentially therapeutic context. We focused on 
Faciocapulohumeral Dystrophy (FSHD) which is a rare autosomal dominant neuromuscular 
disorder with an incidence of 1:14,000 to 1:20,000 characterized by the atrophy of specific 
groups of muscles (10). This pathology is caused by a loss of epigenetic marks within the 
D4Z4 macrosatellite located in the sub-telomeric region of chromosome 4 leading to 
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chromatin relaxation (11). In 95% of the FSHD patients (named FSHD1), this chromatin 
relaxation is associated with a contraction of the D4Z4 array (12, 13). The remaining 5% of 
the FSHD patients (named FSHD2) do not present a contraction of D4Z4 but the vast majority 
of them carry a mutation in the epigenetic modifier gene SMCHD1 (14, 15) . This loss of 
epigenetic marks, when associated with a permissive chromosome 4 (ie carrying the 4qA 
haplotype containing the ATTAAA PAS commonly found in human (16)), leads to the 
aberrant transcription of a double homeobox transcription factor named DUX4 whose ORF is 
present in each D4Z4 repeat (17). DUX4 protein and mRNA have been robustly detected in 
adult and fetal FSHD1 and FSHD2 cells and biopsies whereas they can be found at very low 
levels in control (18-21)DUX4 mRNA is only expressed in 1/1000 nuclei but DUX4 protein 
can be found in 0.5-9% of nuclei (18, 22), suggesting that although DUX4 is not transcribed 
in most nuclei, the resulting protein may spread further (23). DUX4 is a transcription factor 
and its overexpression is described to disturb several cellular pathways (23-30). Moreover, it 
was shown that even if DUX4 expression has not been directly linked to patient’s phenotype, 
DUX4 may play a major role in the pathophysiology of FSHD because : (i) it has been shown 
that at least one D4Z4 repeat is needed for FSHD onset (31), (ii) only alleles with the 4qA 
type (containing the AUUAAA PAS for DUX4 mRNA) are associated with FSHD (32, 33), 
(iii) contraction of the D4Z4 array on chromosome 10 which carries a mutated PAS 
(AUCAAA) does not lead to FSHD (16), (iv) DUX4-induced gene expression is the major 
molecular signature in FSHD skeletal muscles (34), and (v) DUX4 expression is the common 
point between FSHD1 and FSHD2 patients (16).  
Several therapeutic strategies targeting DUX4 expression have been proposed in the literature: 
RNA interference, 2’-O-methyl antisense oligonucleotides (AO) targeting intron-exon 
junctions or over-expression of truncated DUX4 (27, 35-37). Here we describe a new 
therapeutic AO-based therapeutic approach for FSHD using phosphorodiamidate morpholino 
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oligomers (PMOs) targeting the key elements of 3’end processing of the DUX4 transcript and 
which represent the key disease-permissive feature of the FSHD1 and 2 locus. Indeed, during 
the past 10 years, synthetic AOs have emerged as a promising strategy for drug therapy of 
genetic disorders affecting skeletal muscles such as the muscular dystrophies and motor-
neuron diseases. PMOs have been mainly described to bind with high affinity the targeted 
pre-mRNAs and mRNAs and to form a stable hybrid that efficiently blocks access of splicing 
or translation machineries (so-called steric blocking AOs). PMOs can also  form a structure 
mimicking a tRNA precursor which is recognized by RNaseP leading to mRNA cleavage  (for 
review see (38, 39)). Numerous studies investigating the therapeutic potential of antisense 
technology have been already performed and several clinical trials are now in progress for 
muscular dystrophies (40-43).  
In this article, we choose to target the 3’ key elements of DUX4 pre-mRNA, focusing on the 
disease-permissive PAS, the cleavage site and the U/GU-rich DSE sequence. We 
demonstrated in vitro that targeting the 3’ end elements of mRNA with antisense drugs can be 
an efficient therapeutic strategy for a genetic disease. We observed that targeting DUX4 3’key 
elements leads to an efficient extinction of DUX4, may redirect the mRNA cleavage site and 
prevents aberrant expression of genes downstream of the DUX4 transcription factor.  
 
RESULTS 
Determination of 3’end key elements of DUX4 mRNA and PMO design 
For muscle tissue, one PAS (AUUAAA) has been described for DUX4 mRNA, located 766 
bp downstream of the stop codon in genomic DNA (16). Because the DUX4 gene gives rise to 
two DUX4-FL isoforms (DUX4-FL1 with spliced intron 1 and DUX4-FL2 with non-spliced 
intron 1), the cleavage site of DUX4 was precisely determined by RT-3’RACE-PCR using 
primers allowing the detection of each isoform. Total RNAs were extracted from FSHD 
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myotubes at day 4 of differentiation when DUX4 expression is the highest (21). The 
sequences of the PCR products revealed the presence of 3 different cleavage sites located 16 
to 22 bp after the PAS for both DUX4-FL1 and -FL2 DUX4 isoforms (Fig. 1A-B). However, 
these cleavage sites are not used at the same frequencies. The cleavage site located 22 bases 
downstream of the PAS represents 78% of the DUX4-FL1 isoforms but only 41% of DUX4-
FL2 isoforms thus showing the interplay between mRNA cleavage site and splicing (Fig. 1A-
B). In order to investigate the therapeutic potential of AONs targeting 3’ key elements of 
DUX4 mRNA, we designed AONs covering either the PAS (PMO-PAS), the cleavage sites 
and the polyA (PMO-CS1 to 3) or the U/GU-rich (PMO-DSE) sequence (Fig. 1C). Briefly, 
PMOs were designed to (i) contain little or no self-complementarity (ii) form no more than 16 
contiguous intrastrand hydrogen bonds (iii) contain no more than 9 total guanines (>36% G) 
or more than 3 contiguous guanines to ensure good water solubility, and (iv) where possible 
to target more than one of the 3’ key elements with one PMO. For these reasons, the cleavage 
site PMOs contains either a single mismatch to target (PMO-CS2 and PMO-CS3) or do not 
target contiguous bases (PMO-CS1). These PMOs were of varying lengths (25mers to 
30mers) (Table 1). 
 
PMOs induce a down expression of DUX4 mRNA  
The efficacy of each PMO was evaluated in a dose dependent manner after transfection into 
differentiated immortalized FSHD clones. Total RNAs were extracted from myotubes and 
RT-PCR allowing the detection of either DUX4-all (Fig. 2A), or DUX4-FL1 and -FL2 (Fig. 
2B) was performed. No modification of DUX4-all mRNA was observed with PMO-control 
compared to unlipofected cells thus showing that introduction of PMO-control does not 
modify DUX4 expression. With PMO-CS1, –CS2 and -DSE, 27% +/- 5, 25% +/- 17and 36% 
+/- 10 reduction of DUX4-all mRNA was observed respectively at the highest PMO 
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concentration used compared with PMO-control (Fig. 2A). The highest efficacies were 
obtained with the PMO-PAS and –CS3 for which a dose-dependent reduction of DUX4-all 
levels was observed with 40% +/- 6 and 52% +/- 7 inhibition at 50nM respectively (Fig. 2A). 
These two antisense oligonucleotides were investigated further to ascertain if both DUX4 
isoforms were identically targeted by them. A decreased expression of both isoforms was 
observed at 50nM when primers allowing the detection of both DUX4-FL1 and FL-2 (DUX4-
3’UTR oligonucleotides) were used (Fig. 2B).  
 
PMO-CS3 induces a redirection of cleavage region 
Because 22 to 54% of human mRNA have more than one poly(A) sites (4, 5), and because 
redirections of the poly(A) signal have been described in the presence of antisense 
oligonucleotides targeting the poly(A) of other mRNAs (44, 45), in silico analyses were 
performed which revealed the presence of putative alternative poly(A) signal downstream of 
exon 3 (Fig. 3A). A redirection of the poly(A) and/or cleavage sites was thus investigated in 
the presence of the different PMOs at the highest concentration by 3’RACE nested PCR using 
forward primers located in exon 3. A switch in clea age site or poly(A) usage was not 
observed with any of the PMOs except PMO-CS3 (Fig. 3B). The sequence of this 
supplemental band revealed that the cleavage site of the residual DUX4 mRNA in the 
presence of PMO-CS3 was ~40 nt upstream of the canonical cleavage site (Fig. 3C), thus 
suggesting that an alternative poly(A) signal was used to generate this new cleavage site. 
However, in silico analysis of the genomic region upstream of this alternative cleavage site 
(up to DUX4 exon2) did not reveal the presence of any of the 13 PAS previously described 
(4). This new cleavage site is used in approximatively 20% of the residual DUX4 mRNAs. 
 
Page 7 of 33 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
8 
 
PMO-PAS and –CS3 induce a knockdown in expression of genes downstream of DUX4 
in FSHD cells 
Because DUX4 protein is very hard to detect, expression levels of DUX4 biomarkers were 
investigated. Indeed, DUX4 being a transcription factor, the expression levels of several genes 
downstream of DUX4 have been described to be modulated after DUX4 expression among 
them TRIM43, MBD3L2 and ZSCAN4 (21, 27, 46). the expression of these three genes was 
determined by RT-qPCR in the presence of the PMOs in a dose dependent manner. No 
significant modulation of their expressions was observed in the presence of PMO-control 
compared to unlipofected condition. PMO-CS1, -CS2 and –DSE moderately modulate 
expression of genes downstream of DUX4 at the lowest concentrations used but a down 
expression of TRIM43 is observed at the highest concentration. The best modulation of the 
genes downstream of DUX4 was observed in the presence of PMO-PAS and –CS3 in a dose 
dependent manner (Fig. 4).  
Since we have previously published that DUX4 is able to spread from one FSHD nucleus to 
neighboring nuclei thus inducing an aberrant activation of genes downstream of DUX4 in 
many nuclei (23), one possible explanation for the lower expression of TRIM43, MBD3L2 and 
ZSCAN4 observed in the presence of the PMO-PAS and –CS3 could have been an inhibition 
of myotube formation mediated by the PMOs. PMO-transfected cells were immunostained 
with the MF20 antibody recognizing all the myosin heavy chains (Fig. 5A) and fusion indexes 
were calculated by counting the number of nuclei in MF20-positive myotubes containing 3 or 
more nuclei as the percentage of total number of nuclei (Fig. 5B). No statistically significant 
differences were observed with PMO treatment thus showing that the downregulation of the 
genes downstream of DUX4 in the presence of the PMOs was not due to myotube formation 
impairment but rather to lowered DUX4 expression.  
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No significant off-targets are predicted 
The potential off-target effects were also evaluated, PMOs targeting the DUX4 transcript were 
submitted to short-input-sequence BLAST searches against coding and non-coding human 
genome nucleotide collection databases (nr/nr and nr/nt: see Table 3). According to BLAST a 
very strong match is considered to have E-value of <1e-04, whereas a poor match has E-value 
>1e-03. For each PMO, the two BLAST returns showing highest alignment scores (lowest E-
values) were selected for further analysis. With the exception of PMO-CS1 which contains 
specifically selected deletions, all designed PMOs returned a very strong match to the desired 
DUX4 transcript (E-value ≤ 2e-05), whereas all of the off-target gene candidates show high E-
values >0.5. Predicted off-target sequence matches that showed homology on their negative or 
forward strand, corresponding to RNA transcript, were selected for calculation of total free 
energy of binding using the RNAup Server (Table 3; Supplementary figure S1). The only 
potential off-target interactions on the RNA transcript (ie negative strand) was GYS2 for 
PMO-PAS and PTPRT for PMO-CS1, but overall free energies of binding were low (-16.62 
and -6.60 respectively), and with major mismatches (8/21 and 12/29, respectively). These data 
suggest a low probability of interference of any of the designed PMOs targeting DUX4 with 
off target RNAs. 
 
DISCUSSION 
Several strategies using antisense oligonucleotides have been described during the last 
decade. Upon binding, AOs can alter the original function of the targeted mRNA through an 
array of different mechanisms. In the literature, AOs have been described to (i) prevent 5’cap 
formation, (ii) bind the pre-mRNA to modulate splicing by masking the splicing sequences to 
force exon inclusion or exclusion, (iii) induce mRNA degradation after the recognition of the 
duplex AO-mRNA (depending on the chemical modification used), (iv) inhibit ribosome 
Page 9 of 33 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10 
 
access to the mRNA leading to the suppression of protein translation, (v) modulate 
polyadenylation selection in transcripts with more than one poly(A) in their 3’UTR (for 
review see (39)). However, to our knowledge, the possibility to target the 3’UTR key 
elements of the mammalian pre-mRNA to inhibit the polyadenylation in genetic diseases has 
not been studied.  
As previously described, defects in mRNA 3’ end formation can result in disruption of gene 
expression processes in a number of ways, including: transcription termination; transport of 
the mRNA from the nucleus to the cytoplasm; stability of the mRNA; translation efficiency 
and the inhibition of polyadenylation, which in turn might lead to gene silencing (for review 
see (47)). In this study we investigate the possibility of interference in the 3’end mRNA 
processing as a therapeutic approach in the FSHD model. Since FSHD is a gain of function 
disease, characterized by the aberrant over-expression of the DUX4 gene, the therapeutic 
strategies should therefore be based on gene silencing rather than gene rescue. Here we show 
that targeting the 3’ end elements involved in mRNA processing is an effective way to 
decrease DUX4 expression and prevent aberrant expression of genes downstream of DUX4.  
Among the 5 AONs tested, only 2 of them lead to a significant decrease of DUX4 mRNA 
levels under the conditions evaluated. PMOs length could play an important role in their 
efficacies, since PMO-CS3 is the only 30-mer used in this study and is the antisens 
oligonucleotide showing the best efficiency. The number of mismatches could also play a role 
affecting their relative activity when compared to a completely homologous sequence of equal 
length. Secondary structures may also have affected effectiveness of the PMOs and secondary 
structures of exon 3 of DUX4 or the AON were analyzed in silico using thermodynamic 
methods. Indeed, the probability of interaction between the AON and the targeted mRNA can 
be impacted by the presence of closed or opened conformations at the site of hybridization 
(47). When calculating the minimum free energy of a folded mRNA molecule using mfold 
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(http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form2.3) (48, 49), the exon 3 of DUX4 
was predicted to form highly stable secondary structure with free energies of – 56.3 kcal/mol 
(Fig. 6). The resulting outputs show that DUX4 poly(A) is located within the region of an 
open confirmation, whereas the cleavage site and the DSE lay within a closed region. The 
PAS thus appears more accessible than the DSE and this could explain the low efficacy of the 
PMO-DSE which totally overlap a closed region.  
Different mechanisms may be involved in the down-regulation of the targeted mRNA in the 
presence of the PMOs. The first one is that the duplex formation of the PMO with the mRNA 
3’UTR could prevent poly(A) tail elongation. The second one could be the removal of the 
entire tail mediated by a deadenylase-dependent cutting of the poly(A) tail as previously 
described in zebrafish (50), thus affecting mRNA stability. Another possibility is that spatial 
rearrangements of the 3’UTR in the presence of the PMO could have modulated the nonsense 
mediated decay (NMD) pathway (51). In one hand, it was previously shown that NMD is an 
endogenous suppressor of DUX4 mRNA that contributes to the low expression of DUX4 in 
FSHD cells (30). But in the other hand, DUX4 expression was also described to inhibit NMD 
by decreasing UPF1 levels (30). The PMO-DUX4 duplex formation, causing a destabilization 
of DUX4 mRNA by at least one of the mechanisms described earlier, could have thus 
increased NMD activity, enhancing DUX4 repression. 
Recent discoveries have revealed that many human genes use more than one poly(A) and 
cleavage sites, indicating that alternative polyadenylation (APA) is a widespread 
phenomenon. The use of APA has been described to play important roles in several human 
diseases such as (i) in Oculopharyngeal muscular dystrophy (OPMD), in which mutations in 
PABPN1 result in a global enhancement of usage of proximal cleavage sites, leading to an 
unbalanced formation of alternative mRNA 3’ends and to a modification of gene expression 
through aberrant microRNA regulation (52); (ii) in β−thalassemia, in which a loss-of-function 
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of globin 3’ end processing linked to an alteration of the poly(A) site is one of the causes of 
this disease, resulting in the generation of an unstable transcript that is ~900 nt longer (for 
reviews see (1, 7)); (iii) a single nucleotide polymorphism in the U/GU rich region 
downstream of an alternative poly(A) signal in the Fibrinogen gamma haplotype 2 (FGG-H2) 
gene has been shown to affect the usage of this poly(A) and has been associated with 
increased risk of deep-venous thrombosis (53). Considering that the use of antisens 
oligonucleotides targeting the poly(A) site can lead to the use of APA and cleavage site (44, 
45), one important point raised in our experiments was to determine if such a redirection was 
observed in the presence of the PMOs. Although in the presence of PMO-CS3 the cleavage 
site was detected to be redirected by ~40 nt upstream of its normal position, it was still 
considerably distal to any of the previously described alternative poly(A) signals (4). 
Interestingly, this finding does not fit with the current consensus describing that there are 4 
general classes of APA, including: tandem 3’UTR APA; alternative terminal exon APA; 
intronic APA; and internal exon APA (1). This could be explained by the steric congestion at 
the PAS and cleavage site provided by the PMO-CS3 and the cellular proteins involved in the 
polyadenylation process, respectively. The cleavage factors would be then forced to cleave 
the pre-mRNA upstream of the poly(A) signal, resulting in a new cleavage site but still 
utilizing the original poly(A) site. Importantly, in the 14 sequences analyzes, the same 
cleavage region was observed, strongly suggesting a specificity to the target sequence. 
Alternatively, a novel APA was used that has not been previously described (4).  
A redirection of the cleavage site associated to the alternative poly(A) site located in exon 7 
of DUX4 was not observed either. It was shown that chromosomes 4 and 10 produce DUX4 
mRNA in human testes (18). These transcripts can use alternative 3’ exons with a poly(A) 
signal in exon 7, leading to a DUX4 mRNA carrying exons 1-2-6-7 or exons 1-2-4-5-6-7. 
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Exons 3 and 7 thus seem to be mutually exclusive. It is therefore not surprising to not observe 
a redirection of the cleavage site to exon 7 when exon 3 is targeted. 
Targeting the 3’end elements of mRNA could thus represent an alternative approach for gene 
silencing compared to classic antisense oligonucleotide approaches leading to exon skipping, 
translation inhibition, or mRNA destruction into the cytoplasm. The strategy to interfere with 
the mRNA 3’ end processing provides a number of advantages. First, polyadenylation is a 
crucial step required for the maturation of almost all eukaryotic mRNAs (except for histones), 
meaning that virtually any mRNA can be subjected to this strategy. Second, genes with only 1 
exon can be targeted using AON hybridizing the 3’end key elements. Third, AON targeting 
the poly(A) signals may be investigated in a therapeutic context for some disease caused by 
utilization of inadequate APAs. For example, some mantle cell lymphoma patients express 
isoforms of cyclinD1 mRNA with short 3’UTR compared to healthy individuals. Shortening 
of the 3’UTR is caused by the mutations in the CCND1 gene leading to the creation of a 
premature poly(A) signal. This mutated mRNA lacks most of the 3’UTR region that contains 
mRNA destabilizing elements, making the CCDN1 mRNA abnormally stable (54). Therefore 
targeting a premature poly(A) with AON to promote the use of the distal poly(A) may also 
serve as an promising approach to treat disease.  
 
 
MATERIAL AND METHODS 
PMO were manufactured and supplied by Gene Tools (LLC, Philomath, USA). The DNA 
leashes for PMO transfection were synthesized by Eurogentec and their sequences are 
indicated in table 1. Before transfection, the PMOs (2.5 µl at 1 mM) were annealed with the 
leash (25 µl at100 µM) in final volume of 50µL (12.5µL of PBS10X and 10µL of RNAse-free 
water) (final concentration of leashed PMO 50 µM) using the following protocol: 95ºC for 
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5min, 85ºC for 1min, 75ºC for 1min, 65ºC for 5min, 55ºC for 1min, 45ºC for 1min, 35ºC for 
5min, 25ºC for 1min and then held at 15ºC. Efficient annealing was verified using gel 
electrophoresis band shift as previously described (55). Leashed PMOs were stored at 4ºC. 
Immortalized FSHD clones have been characterized previously (56). Cells were cultivated in 
proliferation medium [4 vols of DMEM (Dulbecco’s modified Eagle medium), 1 vol of 199 
medium, FBS (Fetal Bovine Serum) 20%, gentamycin 50µg/mL (Life Technologies, Saint 
Aubin, France)] supplemented with insulin 5µg/mL, dexamethasone 0.2µg/mL, β-FGF 
0.5ng/mL, hEGF 5ng/ml and fetuine 25µg/mL. The differentiation was induced by replacing 
the proliferation medium by DMEM supplemented with insulin (10µg/mL). Two days after 
the induction of differentiation, the transfections were realized using Lipofectamine® 
RNAiMax Reagent (Life Technologies) according to the manufacturer’s instructions. Cells 
were harvested at day 4 of differentiation. 
RNA extraction from cultured cells was performed using Trizol according the manufacturer’s 
protocol (Life Technologies, Saint Aubin, France). RNA concentration was determined using 
a nanodrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, USA). Reverse 
transcription was performed on 1µg of total RNA in 10µl final volume (Roche Transcriptor 
First Strand cDNA Synthesis Kit, Roche, Meylan, France) with a NVT primer 
(GCGAGCTCCGCGGCCGCGTTTTTTTTTTTVN) (10µM) according to the manufacturer 
instructions. The PCR for DUX4-all was performed on 1µL of cDNA using 2X Reddy Mix 
PCR Master Mix (Thermo Scientific) according the manufacturer’s instructions. The PCR 
program was the following: 94ºC for 5min, followed by 35 cycles at 94ºC for 20 s and 60ºC 
for 20 s and 72ºC for 20s, finished with 72ºC for 7min. Quantitative PCR (qPCR) was 
designed according to the MIQE standards (57). The primers used for both PCR and qPCR 
are indicated in table 2. Quantitative PCRs were performed in a final volume of 9µL with 4µL 
of RT product, 0.18µL of each forward and reverse primers at 20µM, and 4.5µL of SYBR® 
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Green mastermix 2X (Roche, Meylan, France) in a lightcycler LC480 (Roche). The qPCR 
cycling conditions were 94ºC for 5min, followed by 50 cycles at 94ºC for 10s and 60ºC for 5s 
and 72ºC for 5s. All the amplicons were validated using sequencing. B2M was the most 
appropriate gene for normalization: a multiparametric analysis of variance (MANOVA) and a 
Newman-Keuls post-hoc test did not reveal any correlation between B2M expression and 
PMO addition (at different concentrations).  
For the 3’RACE, the RT was realized with an oligo dT adapter primer: 
(GCTGTCAACGATACGCTACGTAACGGCATGACAGTGTTTTTTTTTTTTTTTTTTTT
TTTT) as described in table 2. The primary PCRs were performed in a final volume of 15µL 
with 1uL of RT product, 3µL of reverse primer at 20µM (Table 2) and 1µL of primer at 
20µM, 7.5µL 2X ReddyMix PCR Master Mix (Thermo Scientific). The PCR cycling 
conditions were 94ºC for 5min, followed by 5 cycles at 94ºC for 20 s and 72ºC for 50 s, then 
5 cycles at 94ºC for 20s and 70ºC for 30s and 72ºC for 20s, and 25 cycles at 94ºC for 20s and 
68ºC for 20s and 72ºC for 30s, finished with 72ºC for 7min. The nested PCRs were realized in 
a final volume of 15µL with 1µL of primary PCR product, 1µL of reverse and/or forward 
primers 20µM, 7.5µL 2X ReddyMix PCR Master Mix (Thermo Scientific). The PCR cycling 
conditions were 94ºC for 5min, followed by 35 cycles at 94ºC for 20s and 60ºC for 20s and 
72ºC for 30s, finished with 72ºC for 7min. Nested PCR products were purified according 
Nucleospin Gel and PCR Clean Up manufacturer instructions (Macherey-Nagel). Fragments 
were cloned into TOPO TA vector with TOPO TA Cloning kit (Lifetechnologies). Cleavage 
sites were determined by sequencing at least 10 colony-forming units. 
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 FIGURES LEGENDS 
Figure 1: 3’end key elements of DUX4 mRNA and PMO design.  
A and B: To determine the cleavage sites of DUX4 mRNA, a RT using an oligo dT adapter 
primer was realized on total mRNAs isolated from FSHD myotubes at day 4 of 
differentiation. The 3’RACE-PCR was performed using forward primer matching exon 1 and 
reverse primer recognizing the adapter. The PCR products were cloned into a TOPO-TA 
plasmid and 27 and 17 clones were sequenced for DUX4-FL1 (A) and –FL2 (B) respectively. 
The frequencies of the cleavage site usages are indicated. Arrows indicate the location of the 
primers used. The poly(A) site is bolded and underlined and the poly(A) tail is in bold. 
C: Sequences recognized by the different PMOs targeting DUX4. The position +1 is defined 
as the first base of the poly(A) site. The sequences recognized by the PMOs are indicated as 
well as their position on the mRNA. Deletions are represented by hyphen (-). Nucleotidic 
substitutions are indicated.  
 
Figure 2: DUX4 expression in the presence of the PMOs 
Immortalized FSHD myotubes were transfected with PMOs in a dose dependent manner. (A) 
The percentage of residual DUX4-all mRNA was measured by semi quantitative PCR using 
ImageJ software on gel scans. Independent transfections for PMO-control, -PAS, -CS1, -CS2, 
CS3, and -DSE (n≥6) were performed. Values are compared to unlipofected conditions. All 
data represent mean +/- Standard Error of Mean (SEM). A multiparametric analysis of 
variance and a Newman–Keuls post hoc test were performed (*p<0.05; **p<0.01; 
***p<0.001). (B): Representative RT-PCR analysis using DUX4-3’UTR primers in the 
presence of PMO-control, PAS, and -CS3 at 50 nM. As a negative control, a PMO targeting a 
human β-globin mutation that causes β-thalassemia was be used. B2M was used as the 
reference (housekeeping) gene.  
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Figure 3: PMO-CS3 induces a switch in cleavage site usage.  
A redirection of poly(A) usage was investigated in the presence of the different PMOs. (A) In 
silico analyses and literature (18) reveal the presence of alternative polyadenylation site in the 
subtelomeric region of chromosome 4. (B) 3’RACE nested PCR using forward primers 
located in exon 3 shows a switch in cleavage site only in the presence of PMO-CS3. The 
bands with (**) or without (*) a redirection of the cleavage site are indicated. (C) Sequence of 
the most abundant mRNA carrying the redirected cleavage site (DUX4 pre-mRNA). The 
sequence of poly(A) site is underlined and bolded. The poly(A) tail is in bold. The frequencies 
of each variant showing alternative cleavage site usage are indicated (14 analyzed sequences). 
 
Figure 4: Expression of the genes downstream of DUX4 in presence of the PMOs 
Expression levels of TRIM43 (A), ZSCAN4 (B) and MBD3L2 (C) were measured by RT-
qPCR in FSHD myotubes (4 days of differentiation) in the presence of the PMOs at different 
concentrations and compared to the PMO control at the same concentration. Values are 
compared to unlipofected conditions. B2M was used as a normalizer. Data represent mean +/- 
standard error of mean from independent transfections for PMO-control, -PAS, -CS1, -CS2, 
CS3, and -DSE (n≥6). A multiparametric analysis of variance and a Newman–Keuls post hoc 
test were performed (*p<0.05; **p<0.01; ***p<0.001).  
 
Figure 5: Fusion index of immortalized FSHD myotubes in the presence of the PMOs 
Immortalized FSHD myotubes were transfected at day 2 of differentiation with the different 
PMOs at 50 nM. At day 4 of differentiation, cells were stained with MF20 antibody 
recognizing all the myosin heavy chain and counterstained with Dapi (A). Fusion indexes 
were calculated by counting the number of nuclei in myotubes containing more than 2 nuclei 
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as the percentage of total number of nuclei (B). The transfections were performed 6 times for 
the unlipofected, 4 times for PMO-control, -PAS –DSE, and 2 times for PMO-CS1, CS2-, 
CS3. In each experiment, 1000 nuclei were counted. All data represent mean +/- Standard 
Deviation (SD).  
 
Figure 6: Secondary structure predictions of DUX4 mRNA 
Mfold analysis was performed on the 3’ end of DUX4 (starting first nucleotide of exon 3 and 
ending 230 nucleotides downstream). The poly(A) signal and the cleavage region are boxed in 
red. The positions of the sequences recognized by the PMOs are in yellow for the PMOs 
inducing a strong down-regulation of DUX4, whereas the others are in blue. Examples of 
opened and closed RNA secondary structures are indicated.  
 
TABLE LEGENDS 
Table 1: Characteristics of the PMOs 
 
The locations, the PMO sequences and the leash sequences (uppercases indicate the 
complementary region between leash and PMO, lowercases indicates the free ends), the 
percentage of GC and the lenght are shown.  
 
Table 2: Primers used in this study 
PMO name PMO sequence 5'-3' Leash sequence 5'-3' Length (bp) %GC
PMO-PAS (-13 +12) GGGCATTTTAATATATCTCTGAACT gattgGATATATTAAAATGCCCgtgat 25 0.32
PMO-CS1 (-5 +32) CTATAGGATCCACAGGGCATTTTAATATC gttacCCCTGTGGATCCTATAGgtgat 29 0.38
PMO-CS2 (-1 +27) GGATCCACAGGGAGGAGGCATTTTAATA gattgTCCTCCCTGTGGATCCgtgat 28 0.46
PMO-CS3 (+2 +31) TATAGGATCCACAGGGAGGAGGCATTTTAA gaatgTCCCTGTGGATCCTATAgtgat 30 0.43
PMO-DSE (+32 +56) CATCACACAAAAGATGCAAATCTTC gattgGCATCTTTTGTGTGATGgtgat 25 0.36
PMO-Control CCTCTTACCTCAGTTACAATTTATA gattgTAACTGAGGTAAGAGGgtgat 25 0.32
N.A. : Non applicable
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Table 3: Prediction of the anti-DUX4 off target candidates 
 
Each PMO sequence was run thought the BLAST software, optimised for short input 
sequences and limited to human and nt/nr database. Overall binding energy was calculated 
only for the predicted targets that show sequence homology with the PMO on their negative 
strand (-). The units of ∆Gi are expressed in kcal/mol. Abbreviations: IL1RAPL2, interleukin 
1 receptor accessory protein-like 2; GYS2, glycogen synthase 2; C1ORF101, chromosome 1 
open reading frame 101; PTPRT, protein tyrosine phosphatase receptor type T; OTOF, 
otoferlin; POR, P450 cytochrome oxidoreductase; TCRA/TCRD, T cell receptor alpha delta 
locus; KCNJ6, potassium channel inwardly rectifying subfamily J member. 
 
 
Targeted gene Primer Accession number Sequence Location Size (bp)
qPCR efficiency 
(calculated from slope)
Oligo_dT_3'RACE N.A.
GCTGTCAACGATACGCTACGTAACGGCATGA
CAGTGTTTTTTTTTTTTTTTTTTTTTTTT
N.A N.A N.A
Oligo_NVT N.A. GCGAGCTCCGCGGCCGCGTTTTTTTTTTTVN N.A. N.A N.A
DUX4-all_fw CCCAGGTACCAGCAGACC Spanning Exon2-Exon3
DUX4-all_rev TCCAGGAGATGTAACTCTAATCCA Exon3
DUX4-3'UTR_fw AGGCGCAACCTCTCCTAGAAAC Exon1
DUX4-3'UTR_rev TCCAGGAGATGTAACTCTAATCCA Exon3
B2M_fw CTCTCTTTCTGGCCTGGAGG Exon1
B2M_rev TGCTGGATGACGTGAGTAAACC Exon2
MBD3L2_fw CGTTCACCTCTTTTCCAAGC Exon1
MBD3L2_rev AGTCTCATGGGGAGAGCAGA Exon2
TRIM43_fw ACCCATCACTGGACTGGTGT Exon6
TRIM43_rev CACATCCTCAAAGAGCCTGA Exon7
ZSCAN4_962U20_fw CTGGAGCAGTTTATGATTGG Exon3
ZSCAN4_rev AGCTTCCTGTCCCTGCATGT Exon4
3RACE_3’_Primer_rev N.A. GCTGTCAACGATACGCTACGTAACG N.A. N.A N.A
3RACE_3’_Nested_rev N.A. CGCTACGTAACGGCATGACAGTG N.A. N.A N.A
3RACE_Exon1_fw CTCTCCTAGAAACGGAGGCCCCG Exon1 N.A N.A
3RACE_Exon1_Nested_fw CTCGCTGGAAGCACCCCTCAGC Exon1 N.A N.A
3RACE_3’_Exon3_fw CGCACCCCGGCTGACGTGCAAG Exon3 N.A N.A
3RACE_3’_Exon3_Nested_fw CGCTGGCCTCTCTGTGCCCTTG Exon3 N.A N.A
N.A. : Non applicable
N.A.
DUX4-3'UTR
HQ266760 (DUX4-fl1 ) and 
HQ266761 (DUX4-fl2 )
368bp and 
504bp
N.A.
RT-
oligonucleotides
PCR 
oligonucleotides
DUX4-all ENSG00000260596 164bp
67bp 100%
MBD3L2 NM_144614.3 142bp 106%
100bp 109%
ZSCAN4 NM_152677.2 162bp 98%
TRIM 43
3'RACE-PCR 
oligonucleotides
DUX4
ENSG00000260596
ENSG00000260596
NM_138800.1
qPCR 
oligonucleotides
B2M NM_004048.2
Overall free binding energy
(∆Gi)
DUX4 4,00E-05 100 25/25 - Non-coding -32.04
IL1RAPL2 0.58 72 18/25 + N.A N.A.
GYS2 2.3 68 17/25 - Non-coding -16.62
C1ORF101 0.91 72 21/29 + N.A. N.A.
DUX4 3.6 59 17/29 - Non-coding -21.82
PTPRT 3.6 59 17/29 - Non-coding -6.60
DUX4 2,00E-05 96 27/28 - Non-coding -38.02
OTOF 0.82 75 21/28 + N.A. N.A.
POR 0.82 64 18/28 + N.A. N.A.
DUX4 2,00E-05 97 29/30 - Non-coding -37.93
OTOF 0.99 70 21/30 + N.A. N.A.
POR 0.99 60 18/30 + N.A. N.A.
DUX4 4,00E-05 100 25/25 - Non-coding -27.41
TCRA/TC 0.58 72 18/25 + N.A. N.A.
KCNJ6 2.3 68 17/25 + N.A. N.A.
N.A. : Non applicable
PMO-DSE
PMO name Target name E-value % identity Coding/non-coding
PMO-PAS
PMO-CS1
PMO-CS2
PMO-CS3
No. of base overlap
Predicted homology with 
(+/-) strand 
Page 27 of 33 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 1: 3’end key elements of DUX4 mRNA and PMO design.  
A and B: To determine the cleavage sites of DUX4 mRNA, a RT using an oligo dT adapter primer was 
realized on total mRNAs isolated from FSHD myotubes at day 4 of differentiation. The 3’RACE-PCR was 
performed using forward primer matching exon 1 and reverse primer recognizing the adapter. The PCR 
products were cloned into a TOPO-TA plasmid and 27 and 17 clones were sequenced for DUX4-FL1 (A) and –
FL2 (B) respectively. The frequencies of the cleavage site usages are indicated. Arrows indicate the location 
of the primers used. The poly(A) site is bolded and underlined and the poly(A) tail is in bold.  
C: Sequences recognized by the different PMOs targeting DUX4. The position +1 is defined as the first base 
of the poly(A) site. The sequences recognized by the PMOs are indicated as well as their position on the 
mRNA. Deletions are represented by hyphen (-). Nucleotidic substitutions are indicated.  
180x108mm (300 x 300 DPI)  
 
 
Page 28 of 33Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 2: DUX4 expression in the presence of the PMOs  
Immortalized FSHD myotubes were transfected with PMOs in a dose dependent manner. (A) The percentage 
of residual DUX4-all mRNA was measured by semi quantitative PCR using ImageJ software on gel scans. 
Independent transfections for PMO-control, -PAS, -CS1, -CS2, CS3, and -DSE (n≥6) were performed. Values 
are compared to unlipofected conditions. All data represent mean +/- Standard Error of Mean (SEM). A 
multiparametric analysis of variance and a Newman–Keuls post hoc test were performed (*p<0.05; 
**p<0.01; ***p<0.001). (B): Representative RT-PCR analysis using DUX4-3’UTR primers in the presence of 
PMO-control, PAS, and -CS3 at 50 nM. As a negative control, a PMO targeting a human β-globin mutation 
that causes β-thalassemia was be used. B2M was used as the reference (housekeeping) gene.  
153x117mm (300 x 300 DPI)  
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Figure 3: PMO-CS3 induces a switch in cleavage site usage.  
A redirection of poly(A) usage was investigated in the presence of the different PMOs. (A) In silico analyses 
and literature (18) reveal the presence of alternative polyadenylation site in the subtelomeric region of 
chromosome 4. (B) 3’RACE nested PCR using forward primers located in exon 3 shows a switch in cleavage 
site only in the presence of PMO-CS3. The bands with (**) or without (*) a redirection of the cleavage site 
are indicated. (C) Sequence of the most abundant mRNA carrying the redirected cleavage site (DUX4 pre-
mRNA). The sequence of poly(A) site is underlined and bold d. The poly(A) tail is in bold. The frequencies of 
each variant showing alternative cleavage site usage are indicated (14 analyzed sequences).  
180x116mm (300 x 300 DPI)  
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Figure 4: Expression of the genes downstream of DUX4 in presence of the PMOs  
Expression levels of TRIM43 (A), ZSCAN4 (B) and MBD3L2 (C) were measured by RT-qPCR in FSHD 
myotubes (4 days of differentiation) in the presence of the PMOs at different concentrations and compared 
to the PMO control at the same concentration. Values are compared to unlipofected conditions. B2M was 
used as a normalizer. Data represent mean +/- standard error of mean from independent transfections for 
PMO-control, -PAS, -CS1, -CS2, CS3, and -DSE (n≥6). A multiparametric analysis of variance and a 
Newman–Keuls post hoc test were performed (*p<0.05; **p<0.01; ***p<0.001).  
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Figure 5: Fusion index of immortalized FSHD myotubes in the presence of the PMOs  
Immortalized FSHD myotubes were transfected at day 2 of differentiation with the different PMOs at 50 nM. 
At day 4 of differentiation, cells were stained with MF20 antibody recognizing all the myosin heavy chain and 
counterstained with Dapi (A). Fusion indexes were calculated by counting the number of nuclei in myotubes 
containing more than 2 nuclei as the percentage of total number of nuclei (B). The transfections were 
performed 6 times for the unlipofected, 4 times for PMO-control, -PAS –DSE, and 2 times for PMO-CS1, 
CS2-, CS3. In each experiment, 1000 nuclei were counted. All data represent mean +/- Standard Deviation 
(SD).  
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Figure 6: Secondary structure predictions of DUX4 mRNA  
Mfold analysis was performed on the 3’ end of DUX4 (starting first nucleotide of exon 3 and ending 230 
nucleotides downstream). The poly(A) signal and the cleavage region are boxed in red. The positions of the 
sequences recognized by the PMOs are in yellow for the PMOs inducing a strong down-regulation of DUX4, 
whereas the others are in blue. Examples of opened and closed RNA secondary structures are indicated.  
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